Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, April 18, 2024
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Michael Petusky Maintained (XRAY) at Buy and Held Target at $41 on, Apr 18th, 2024
Michael Petusky of Barrington Research, Maintained "DENTSPLY SIRONA Inc." (XRAY) at Buy and Held Target at $41 on, Apr 18th, 2024.
Michael has made no other calls on XRAY in the last 4 months.
There are 3 other peers that have a rating on XRAY. Out of the 3 peers that are also analyzing XRAY, 1 agrees with Michael's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Jason Bednar of "Piper Sandler" Maintained at Hold with Increased Target to $35 on, Friday, January 12th, 2024
These are the ratings of the 2 analyists that currently disagree with Michael
- David Saxon of "Needham" Reiterated at Strong Buy and Held Target at $42 on, Thursday, February 29th, 2024
- Michael Cherny of "Leerink Partners" Initiated at Buy and Held Target at $42 on, Monday, February 26th, 2024
